Bi2WO6 Semiconductor Nanoplates for Tumor Radiosensitization through High-Z Effects and Radiocatalysis

Zang, Yali; Gong, Lixin; Mei, Linqiang; Gu, Zhanjun; Wang, Qing

doi:10.1021/acsami.9b03636

Cited by 81 publications

(56 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported that poly(vinylpyrrolidone) (PVP)‐modified Bi 2 WO 6 nanoplates, which exhibits strong radiocatalytic activity for water splitting and ROS generation under X‐ray irradiation. [ 224 ] The results indicated that Bi 2 WO 6 nanoplates can effectively enhance radiotherapeutic efficacy. Similarly, in order to further enhance the catalytic activity of radiocatalysts, improving the utilization levels of X‐ray‐induced e − and h + is an essential strategy.…”

Section: Ros‐associated Nanomedicines For Disease Treatmentsmentioning

confidence: 99%

Reactive Oxygen Species‐Regulating Strategies Based on Nanomaterials for Disease Treatment

et al. 2020

Self Cite

View full text Add to dashboard Cite

Reactive oxygen species (ROS) play an essential role in physiological and pathological processes. Studies on the regulation of ROS for disease treatments have caused wide concern, mainly involving the topics in ROS‐regulating therapy such as antioxidant therapy triggered by ROS scavengers and ROS‐induced toxic therapy mediated by ROS‐elevation agents. Benefiting from the remarkable advances of nanotechnology, a large number of nanomaterials with the ROS‐regulating ability are developed to seek new and effective ROS‐related nanotherapeutic modalities or nanomedicines. Although considerable achievements have been made in ROS‐based nanomedicines for disease treatments, some fundamental but key questions such as the rational design principle for ROS‐related nanomaterials are held in low regard. Here, the design principle can serve as the initial framework for scientists and technicians to design and optimize the ROS‐regulating nanomedicines, thereby minimizing the gap of nanomedicines for biomedical application during the design stage. Herein, an overview of the current progress of ROS‐associated nanomedicines in disease treatments is summarized. And then, by particularly addressing these known strategies in ROS‐associated therapy, several fundamental and key principles for the design of ROS‐associated nanomedicines are presented. Finally, future perspectives are also discussed in depth for the development of ROS‐associated nanomedicines.

show abstract

Section: Ros‐associated Nanomedicines For Disease Treatmentsmentioning

confidence: 99%

Reactive Oxygen Species‐Regulating Strategies Based on Nanomaterials for Disease Treatment

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…On this principle, Bi 2 WO 6 semiconductors were harnessed as both radiosensitizing nanoagents for enhancing the X‐ray energy deposition because of the presence of high‐ Z elements of Bi ( Z = 83) and W ( Z = 74) elements. [ 127 ] The semiconductor nature of Bi 2 WO 6 also enabled the radiocatalysis for the ROS production. The concurrent radiation energy deposition and radiocatalysis by Bi 2 WO 6 semiconductors achieved high and synergistic killing effect of cancer cells in vitro and desirable tumor‐suppressing outcome of tumor xenograft in vivo.…”

Section: Radiodynamic Therapymentioning

confidence: 99%

Emerging Nanomedicine‐Enabled/Enhanced Nanodynamic Therapies beyond Traditional Photodynamics

et al. 2021

View full text Add to dashboard Cite

Figure 3. a) Scheme for the constructed Fe(III)/TPPS nanosonosensitizer for synergistic sonotheranostics by RGD-enabled tumor targeting, downregulated SOD2 expression, GSH depletion, Fenton reaction-triggered hydroxyl radicals and SDT. Reproduced with permission. [38] Copyright 2019, Wiley-VCH. b) Schematic illustration of the design principle and mechanism of combinatorial SDT and immunotherapy, including nanosonosensitizer-enabled and SDT-induced antitumor immune responses and checkpoint blockade for tumor immunotherapy. Reproduced under the terms of the CC-BY Creative Commons Attribution 4.

show abstract

“…The same results have been reported for the in vivo safety of Bi-based NMs in previous studies. 3,4,29,61,62,74,75…”

Section: Hematology and Blood Biochemistrymentioning

confidence: 99%

A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials

Badrigilan¹,

Heydarpanahi²,

Choupani³

et al. 2020

IJN

View full text Add to dashboard Cite

Here, bismuth-based nanomaterials (Bi-based NMs) are introduced as promising theranostic agents to enhance image contrast as well as for the therapeutic gain for numerous diseases. However, understanding the interaction of such novel developed nanoparticles (NPs) within a biological environment is a requisite for the translation of any promising agent from the lab bench to the clinic. This interaction delineates the fate of NPs after circulation in the body. In an ideal setting, a nano-based therapeutic agent should be eliminated via the renal clearance pathway, meanwhile it should have specific targeting to a diseased organ to reach an effective dose and also to overcome off-targeting. Due to their clearance pathway, biodistribution patterns and pharmacokinetics (PK), Bi-based NMs have been found to play a determinative role to pass clinical approval and they have been investigated extensively in vivo to date. In this review, we expansively discuss the possible toxicity induced by Bi-based NMs on cells or organs, as well as biodistribution profiles, PK and the clearance pathways in animal models. A low cytotoxicity of Bi-based NMs has been found in vitro and in vivo, and along with their long-term biodistribution and proper renal clearance in animal models, the translation of Bi-based NMs to the clinic as a useful novel theranostic agent is promising to improve numerous medical applications.

show abstract

Bi₂WO₆ Semiconductor Nanoplates for Tumor Radiosensitization through High-Z Effects and Radiocatalysis

Cited by 81 publications

References 58 publications

Reactive Oxygen Species‐Regulating Strategies Based on Nanomaterials for Disease Treatment

Reactive Oxygen Species‐Regulating Strategies Based on Nanomaterials for Disease Treatment

Emerging Nanomedicine‐Enabled/Enhanced Nanodynamic Therapies beyond Traditional Photodynamics

<p>A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials</p>

Contact Info

Product

Resources

About